Table 1. Patient and disease characteristics before start of first- and second-line treatment.
| First-line | Second-line | |||
|---|---|---|---|---|
| Real world-data (N = 621) | Average of imputed datasets (N = 621) | Real world-data (N = 101) | Average of imputed datasets (N = 101) | |
| Sex—N (%) | ||||
| Female | 213 (34%) | 213 (34%) | 27 (27%) | 27 (27%) |
| Male | 408 (66%) | 408 (66%) | 74 (73%) | 74 (73%) |
| Median age—yr (range) | 66 (23–93) | 66 (23–93) | 62 (23–79) | 62 (23–79) |
| Histology—N (%) | ||||
| Clear cell | 354 (57%) | 354 (57%) | 69 (68%) | 69 (68%) |
| Other * | 267 (43%) | 267 (43%) | 32 (32%) | 32 (32%) |
| WHO performance status—N (%) | ||||
| 0–1 | 204 (33%) | 430 (69%) | 34 (34%) | 73 (72%) |
| 2–4 | 61 (10%) | 191 (31%) | 9 (9%) | 28 (28%) |
| Missing | 356 (57%) | 58 (57%) | ||
| Site of metastasis—N (%) | ||||
| one | 195 (31%) | 206 (33%) | 19 (19%) | 19 (19%) |
| more than one | 398 (64%) | 415 (67%) | 82 (81%) | 82 (81%) |
| Missing | 28 (5%) | 0 (0%) | ||
| Liver metastasis—N (%) | ||||
| no | 487 (78%) | 509 (82%) | 74 (73%) | 74 (73%) |
| yes | 106 (17%) | 112 (18%) | 27 (27%) | 27 (27%) |
| Missing | 28 (5%) | 0 (0%) | ||
| Lung metastasis—N (%) | ||||
| no | 163 (26%) | 173 (28%) | 21 (21%) | 21 (21%) |
| yes | 430 (69%) | 448 (72%) | 80 (79%) | 80 (79%) |
| Missing | 28 (5%) | 0 (0%) | ||
| Bone metastasis—N (%) | ||||
| no | 375 (60%) | 393 (63%) | 58 (57%) | 58 (57%) |
| yes | 218 (35%) | 228 (37%) | 43 (43%) | 43 (43%) |
| Missing | 28 (5%) | 0 (0%) | ||
| Brain metastasis—N (%) | ||||
| no | 546 (88%) | 571 (92%) | 92 (91%) | 92 (91%) |
| yes | 47 (8%) | 50 (8%) | 9 (9%) | 9 (9%) |
| Missing | 28 (5%) | 0 (0%) | ||
| Prior nephrectomy—N (%) | ||||
| no | 452 (73%) | 453 (73%) | 43 (43%) | 43 (43%) |
| yes | 168 (27%) | 168 (27%) | 58 (57%) | 58 (57%) |
| Missing | 1 (0%) | 0 (0.0%) | ||
| Haemoglobin—N (%) | ||||
| normal | 171 (28%) | 205 (33%) | 20 (20%) | 20 (20%) |
| < LLN | 347 (56%) | 416 (67%) | 78 (77%) | 81 (80%) |
| Missing | 103 (17%) | 3 (3%) | ||
| Neutrophil count—N (%) | ||||
| normal | 203 (33%) | 383 (62%) | 67 (66%) | 88 (87%) |
| > ULN | 108 (17%) | 238 (38%) | 10 (10%) | 13 (13%) |
| Missing | 310 (50%) | 24 (24%) | ||
| Platelet count—N (%) | ||||
| normal | 358 (58%) | 452 (73%) | 66 (65%) | 70 (69%) |
| > ULN | 140 (23%) | 169 (27%) | 29 (29%) | 31 (31%) |
| Missing | 123 (20%) | 6 (6%) | ||
| Albumin—N (%) | ||||
| normal | 247 (40%) | 391 (63%) | 51 (51%) | 75 (74%) |
| < LLN | 136 (22%) | 230 (37%) | 18 (18%) | 26 (26%) |
| Missing | 238 (38%) | 32 (32%) | ||
| Corrected serum calcium—N (%) | ||||
| normal | 243 (39%) | 421 (68%) | 45 (45%) | 72 (71%) |
| > ULN | 116 (19%) | 200 (32%) | 18 (18%) | 29 (29%) |
| Missing | 262 (42%) | 38 (38%) | ||
| Alkaline phosphatase—N (%) | ||||
| normal | 324 (52%) | 432 (70%) | 65 (64%) | 74 (73%) |
| > ULN | 139 (22%) | 189 (30%) | 24 (24%) | 27 (27%) |
| Missing | 158 (25%) | 13 (13%) | ||
| Lactate dehydrogenase—N (%) | ||||
| normal | 277 (45%) | 372 (60%) | 63 (62%) | 71 (70%) |
| > 1.5 times ULN | 174 (28%) | 249 (40%) | 28 (28%) | 30 (30%) |
| Missing | 170 (27%) | 10 (10%) | ||
Abbreviations: LLN, lower limit of normal; ULN, upper limit of normal.
* mRCC was clinically established without histopathological confirmation in 17% of patients and mRCC was classified as not otherwise specified without further subtyping in 13% of patients. It is likely that a substantial proportion of these patients had a clear cell subtype.